A Randomized, Placebo-Controlled, Double-Blind Trial of the Effect of Combined Therapy With Deferoxamine and Deferiprone on Myocardial Iron in Thalassemia Major Using Cardiovascular Magnetic Resonance | Zendy

Mark Tanner | Zendy; R. Galanello | Zendy; C. Dessì | Zendy; Gillian Smith | Zendy; Mark A. Westwood | Zendy; Annalisa Agus | Zendy; Sy Ha | Zendy; R. Assomull | Zendy; SV Nair | Zendy; John M. Walker | Zendy; Dudley J. Pennell | Zendy

Open Access

A Randomized, Placebo-Controlled, Double-Blind Trial of the Effect of Combined Therapy With Deferoxamine and Deferiprone on Myocardial Iron in Thalassemia Major Using Cardiovascular Magnetic Resonance

Author(s) -

Mark Tanner,

R. Galanello,

C. Dessì,

Gillian Smith,

Mark A. Westwood,

Annalisa Agus,

Sy Ha,

R. Assomull,

SV Nair,

John M. Walker,

Dudley J. Pennell

Publication year - 2007

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.106.648790

Subject(s) - deferiprone , medicine , deferoxamine , chelation therapy , thalassemia , randomized controlled trial , magnetic resonance imaging , double blind , placebo , beta thalassemia , cardiology , pathology , radiology , alternative medicine

Cardiac complications secondary to iron overload are the leading cause of death in beta-thalassemia major. Approximately two thirds of patients maintained on the parenteral iron chelator deferoxamine have myocardial iron loading. The oral iron chelator deferiprone has been demonstrated to remove myocardial iron, and it has been proposed that in combination with deferoxamine it may have additional effect.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research